VYNE and Tay Therapeutics reach licence agreement

2nd May 2023 Uncategorised 0

Deal involves an oral BET inhibitor which treats fibrotic and immuno-inflammatory disorders

More: VYNE and Tay Therapeutics reach licence agreement
Source: News